Phase 2 Parkinson's Disease Trial, By Invitation
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with Parkinson's disease and are currently taking a medication called levodopa.
- People whose Parkinson's disease is considered mild to moderate, based on a standard rating scale called Hoehn and Yahr, at stages I, II, or III.
- People who are older than 45 years of age.
- Both men and women may be considered.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose Parkinson's disease is caused by another underlying condition (sometimes called secondary Parkinson's disease).
- People who have previously had a type of brain surgery used to treat Parkinson's disease called stereotactic surgery.
- People who currently have an active cancer diagnosis.
- People who are known to have an allergic or adverse reaction to melatonin.
- People who are currently taking certain medications, including anti-seizure drugs (anticonvulsants), oral contraceptive pills (the pill), or a group of medicines used to treat conditions like rheumatoid arthritis (DMARDs).
- People who have an autoimmune disease (a condition where the body's immune system attacks its own tissues).
- People who are pregnant or currently breastfeeding.
- People who have any significant health condition that the trial site determines could make it unsafe for them to participate or make it difficult to follow them through the study (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
effect of melatonin 2) Antioxidant marker erythrocyte glutathione (GSH) This study involves a comparison of MDA and GSH levels between the control and intervention groups at baseline and after 12 weeks.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.